MedTrace Logo

A Comparison of BNP Levels Using the Nexfin Device in Healthy Pregnant and Preeclamptic Women

NCT02527018 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2018-01-30

No results posted yet for this study

Summary

Primary Endpoint: Quantify the hemodynamic changes in preeclampsia using the non-invasive Nexfin device.

Secondary Endpoint: Determine if measurable hemodynamic changes are statistically correlated with B-type natriuretic peptide (BNP) levels.

Conditions

Interventions

DEVICE

Sphygmomanometer

Non-invasive reliable method of continuous measuring arterial blood pressure in pregnant women. Nextfin provides continuous blood pressure, heart rate, cardiac output, stroke volume, systemic vascular resistance and left ventricular contractility indices.

Sponsors & Collaborators

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Afshan Hameed, MD · University of California, Irvine

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-11-30
Completion
2017-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02527018 on ClinicalTrials.gov